

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/129104 A1

(51) International Patent Classification:

C07D 239/24 (2006.01) A61K 31/427 (2006.01)
C07D 241/10 (2006.01) A61P 11/00 (2006.01)
C07D 277/38 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/060181

(22) International Filing Date:

13 December 2024 (13.12.2024)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,882 15 December 2023 (15.12.2023) US

(71) Applicant: SIONNA THERAPEUTICS INC. [US/US];
21 Hickory Drive, Suite 500, Waltham, Massachusetts
02451 (US).

(72) Inventors: GAO, Zhongli; c/o Sionna Therapeutics Inc.,
21 Hickory Drive, Suite 500, Waltham, Massachusetts
02451 (US). LIAO, Junkai; c/o Sionna Therapeutics Inc.,
21 Hickory Drive, Suite 500, Waltham, Massachusetts
02451 (US). TOPALOV, George; c/o Sionna Therapeutics
Inc., 21 Hickory Drive, Suite 500, Waltham, Massachusetts
02451 (US). MUNSON, Mark; c/o Sionna Therapeutics
Inc., 21 Hickory Drive, Suite 500, Waltham, Massachusetts
02451 (US). HURLBUT, Gregory; c/o Sionna Therapeu-
tics Inc., 21 Hickory Drive, Suite 500, Waltham, Massachu-
setts 02451 (US). MACOR, John E.; c/o Sionna Therapeu-
tics Inc., 21 Hickory Drive, Suite 500, Waltham, Massachu-
setts 02451 (US).

(74) Agent: HALEY, Christopher K. et al.; Goodwin Procter
LLP, 100 Northern Avenue, Boston, Massachusetts 02210
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

(57) Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

WO 2025/129104 A1